Doctolib eyes secondary investment round, valuation may remain flat
Photo by Iraj Ishtiak on Unsplash
Doctolib, a French health tech company valued at $6.4 billion in 2022, is in talks for a secondary investment round, with Generation Investment Management considering buying shares from existing investors. The deal could keep Doctolib's valuation relatively flat, while Mistral has overtaken it as France's most valuable startup with a $14 billion valuation.
Key takeaways
- Doctolib, the French health tech company, is reportedly in preliminary discussions for a secondary investment round potentially reaching hundreds of millions of dollars, according to Forbes
- Generation Investment Management, chaired by Al Gore, is considering acquiring shares from existing Doctolib investors
- While Doctolib reached a valuation of $6
Related Topics
Want coverage like this for your company?
Local & industry wins build trusted proof, SEO/geo signals and prime national editors.
Check fit (2 min)Is this your company?
Set up real-time alerts and keep your Heartspace News coverage accurate. Verified teams can update profiles, request corrections, and collaborate on future stories.
Want to turn mentions into momentum? Find your best path with the Fit Checker. Verified profiles receive a free consult.